Inside GRAPPA

How do biological sex differences shape the clinical presentation and treatment outcomes in psoriatic arthritis (PsA)? In this episode of Inside GRAPPA, Dr. Hanna Johnsson delves into groundbreaking research led by Steven Dang and Dr. Lihi Eder, supported by the GRAPPA Pilot Research Grant. Their study explores sex-related differences in PsA through proteomic analysis, uncovering unique biomarkers and pathways that could redefine personalized medicine for PsA patients.What You'll Learn:The rationale behind investigating sex-specific differences in PsA.  Insights into how immune and inflammatory profiles differ between males and females.  Key findings from proteomic studies, including pivotal proteins and pathways like NETosis, Rho GTPase, and cytokine signaling.  The potential for sex-specific biomarkers to guide diagnosis and treatment in PsA.🔗 Stay Connected with GRAPPA:  Visit the GRAPPA Website for more research updates.  Subscribe to Inside GRAPPA wherever you get your podcasts to stay informed on the latest in PsA research.

In this episode of Inside GRAPPA, Dr. Joel Gelfand joins host Mio Nakamura to discuss a groundbreaking pragmatic trial that may transform access to phototherapy. A long-standing GRAPPA member and trailblazer in dermatologic research, Dr. Gelfand shares insights from the "LITE Study," a patient-centered, nationwide trial comparing home-based vs. office-based phototherapy for psoriasis.You'll hear:   •   Why phototherapy remains a preferred treatment for many patients, even in the biologic era   •   Surprising results comparing office phototherapy to adalimumab (a biologic) in previous trials   •   How skin of color patients may benefit most from home phototherapy---and why   •   Real-world barriers to accessing phototherapy and how the study tackled them head-on   •   What's next: From research findings to implementation science and changing payer coverageThis episode is essential listening for dermatologists, rheumatologists, and researchers passionate about improving access and outcomes for patients with psoriatic disease. Tune in for a conversation that blends clinical science with patient advocacy---and may reshape the standard of care.🧪 Learn more about PCORI's mission: pcori.org
📄 Stay tuned for the full publication of the LITE Study💡 Want to get involved in pragmatic research? Dr. Gelfand shares how you can participate in studies like the CP3 trial—no research background required.🎧 Subscribe to Inside GRAPPA for more deep dives into cutting-edge research on psoriatic disease.

How does multimorbidity impact the progression from psoriasis to psoriatic arthritis? Can early identification of chronic conditions help prevent psoriatic arthritis in high-risk patients?In this episode of Inside GRAPPA, host Dr. Mio Nakamura sits down with Dr. Paras Karmacharya, recipient of a GRAPPA Annual Pilot Research Grant. He presented his findings at the 2024 GRAPPA Annual Meeting in Seattle and shares his groundbreaking study with us on "Multimorbidity and Psoriasis as a Risk Factor for Psoriatic Arthritis." Dr. Karmacharya discusses his personal journey into psoriatic arthritis research, how his study leveraged the Rochester Epidemiology Project, and what the findings mean for the future of patient care. He also explores:  ✔️ What multimorbidity really means in psoriatic disease  ✔️ The connection between chronic conditions and psoriatic arthritis risk  ✔️ How his study design helped uncover key insights  ✔️ The clinical implications for screening, early intervention, and patient educationKey Takeaways  🔹 Multimorbidity matters: Patients with multiple chronic conditions at the time of psoriasis diagnosis had a significantly higher risk of developing psoriatic arthritis.  🔹 Psychiatric and musculoskeletal disorders---such as anxiety, mood disorders, and fibromyalgia---were strongly associated with increased risk.  🔹 A shift in clinical approach is needed: Multidisciplinary care models, early screening, and preventive strategies could improve patient outcomes.Resources & Links  📄 Learn more about GRAPPA's research initiatives: GRAPPA Website  🎧 Listen & subscribe to Inside GRAPPA on your favorite podcast platform.

What if we could predict psoriatic arthritis before it even begins? In this episode of Inside GRAPPA, host Dr. Hanna Johnsson is joined by Professors Oliver Fitzgerald and Steve Pennington to discuss the groundbreaking HIPPOCRATES Project. Funded by the Innovative Healthcare Initiative, this major European research effort is tackling the biggest challenges in psoriatic arthritis (PsA)—from early diagnosis to precision treatment.With 27 partners across academia, industry, and patient organizations, HIPPOCRATES is at the forefront of multi omics research, integrating cutting-edge genomics, proteomics, and imaging technologies to revolutionize PsA care. But what are the biggest hurdles they’ve faced? And how close are they to real-world clinical impact?🔑 Key Takeaways📌 The four major unmet needs in psoriatic arthritis and how HIPPOCRATES is addressing them.📌 How patient representatives are shaping the research and ensuring its relevance.📌 The role of multi omics in predicting PsA progression and improving treatment response.📌 Challenges of coordinating a massive international project and the unexpected roadblocks.📌 Early findings and what they mean for the future of PsA diagnosis and treatment.📢 Resources & Links🔗 Learn more about the HIPPOCRATES Project
🔗 Follow GRAPPA: grappanetwork.org🎧 Listen now on Apple Podcasts, Spotify, or wherever you get your podcasts!💡 Enjoying the podcast? Leave us a review and let us know what topics you’d like to hear next!

In this episode, host Dr. Fabian Proft explores the most impactful research and updates from the EADV 2024 Congress in Amsterdam. Joining him are distinguished Young GRAPPA members Dr. Dimitri Luz, Dr. Ahmet Uğur, and Dr. Margo Gkini, who each share their expert perspectives on groundbreaking studies and their implications for psoriatic disease care.Episode Highlights:What the latest research reveals about psoriasis pathophysiology.  How biologics are impacting long-term treatment safety and efficacy.  Insights into the gut-skin connection and its role in inflammation.Resources and Links:  Learn more about GRAPPA: GRAPPA Official Website  Discover highlights from the GRAPPA EADV 2024 Congress Highlights.🎧 Subscribe to Inside GRAPPA on your favorite podcast platform for more updates on cutting-edge research and clinical strategies in psoriasis and psoriatic arthritis. Don't miss the next episode---stay tuned and stay curious!

How close are we to predicting psoriatic arthritis (PsA) before it strikes? In this episode of Inside GRAPPA, Dr. Fabian Proft sits down with two esteemed researchers, Dr. Axel Svedbom and Professor Mona Ståhle, from the Karolinska Institute in Stockholm, to discuss their groundbreaking study on predicting PsA in patients with new-onset psoriasis. Funded by the GRAPPA Pilot Research Grant, this project is poised to revolutionize early detection and intervention strategies for psoriatic disease.Listen as they discuss:  The innovative predictive models combining machine learning with clinical data.  Key findings, including the significance of arthralgia as a predictive marker for PsA.  How their research could reshape clinical practices and improve patient outcomes.Featured Guests  Dr. Axel Svedbom: Postdoctoral researcher specializing in registry-based research and health economics, with over a decade of focus on psoriasis and psoriatic arthritis.  Professor Mona Ståhle: Dermatologist and researcher dedicated to advancing understanding and treatment of psoriatic disease.Resources & Links  Stay updated with GRAPPA's initiatives: GRAPPA Website.  Explore previous episodes of Inside GRAPPA: Podcast Archive.🎙️ Subscribe to Inside GRAPPA and join the conversation!

How should musculoskeletal symptoms in psoriasis patients be managed---and who should take the lead? In this episode of Inside GRAPPA, Dr. Mio Nakamura moderates a compelling debate featuring Dr. Laura Savage, Consultant Dermatologist from Leeds Teaching Hospital, UK, and Dr. Fabian Proft, Rheumatologist from Berlin, Germany. Together, they tackle the vital question: Should dermatologists or rheumatologists be in the driver's seat when managing psoriatic arthritis (PsA)?Listen as they discuss:  The role of dermatologists in early detection and PsA prevention.    Rheumatologists' emphasis on precise diagnosis and targeted treatment.    The power of collaborative care in improving patient outcomes.Join us for an engaging conversation about the challenges and opportunities in PsA management, and how multidisciplinary approaches can lead to better care for patients with psoriatic disease.Featured Guests  Dr. Laura Savage: Consultant Dermatologist specializing in psoriatic disease, advocating for early intervention strategies in dermatology.    Dr. Fabian Proft: Rheumatologist with expertise in imaging and precision medicine for inflammatory arthritis.Resources & Links  Discover GRAPPA's commitment to collaboration: GRAPPA Website.    Catch up on past episodes of Inside GRAPPA: Podcast Archive.🎙️ Don't miss this episode filled with expert perspectives on psoriatic disease care. Subscribe to Inside GRAPPA and be part of the conversation!

In this insightful episode, host Dr. Sebastian Herrera delves into the critical topic of comorbidities and related conditions in psoriatic disease, alongside experts Professor Kurt de Vlam MD, PhD, Head of Clinic Rheumatology at the University Hospitals Leuven in Belgium and Dr. Alexis Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology at the University of Pennsylvania in the United States.What's inside this episode?Understanding Comorbidities vs. Related Conditions: Discover the distinctions between these two critical aspects and why it's important to differentiate them in psoriatic disease management.Expert Insights: Hear about the influence of comorbidities on treatment choices and patient outcomes.Impact on Treatment: Learn how related conditions and comorbidities affect therapeutic decisions, including the selection of DMARDs.Patient Care: Explore the importance of a comprehensive approach to treating psoriatic disease, addressing both the primary condition and associated health issues.Key Points & Highlights:Definitions and Importance: Clear definitions of comorbidities and related conditions, and their significance in the clinical setting.Treatment Influences: How the presence of comorbidities can alter the choice of therapies and the necessity of personalized treatment plans.Common Comorbidities: Discussion on obesity, cardiovascular disease, depression, and more, and their implications for patient care.Future Directions: The need for ongoing research and proactive management strategies to improve patient outcomes.Why listen?Educational Insight: Gain a deeper understanding of how comorbidities and related conditions impact psoriatic disease.Expert Opinions: Benefit from the knowledge and experience of leading specialists in the field.Comprehensive Care: Learn about the holistic approach to managing psoriatic disease, ensuring better quality of life for patients.Stay Connected:For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode!

Today on Inside GRAPPA, host Sebastian Herrera is joined by Lourdes Perez Chada, an Instructor in Dermatology at Harvard Medical School and a clinical investigator at the Brigham and Women’s Hospital in Boston, and Cheryl Rosen who is the Head of the Division of Dermatology,Toronto Western Hospital and University Health Network Hospitals, a Clinician Investigator at Toronto Western Hospital, and a Professor of the Dept of Medicine, University of Toronto.In this episode, we discuss the importance of nail psoriasis, including the prevalence, manifestations, and diagnosis, and how it affects patients in their daily lives.Key Topics:Prevalence and Diagnosis: Nail psoriasis affects about 50% of patients with psoriasis and up to 90% over their lifetime. The experts discuss clinical diagnostic methods and the challenges in identifying the condition. Tools like biopsies and imaging are rarely used due to their invasiveness.Differential Diagnosis: They examine common conditions that can be mistaken for nail psoriasis, including onychomycosis (fungal infections), lichen planus, and alopecia areata.Impact on Quality of Life: Nail psoriasis has a significant impact, especially in terms of physical pain, mental health, and daily activities. Patients may experience anxiety and depression, particularly when their hands or feet are affected.Association with Psoriatic Arthritis: Nail psoriasis is a risk factor for developing psoriatic arthritis, due to the anatomical connection between the nail and underlying bones. The discussion covers how this link affects prognosis and treatment.Treatment Options: Historically difficult to treat, nail psoriasis management ranges from doing nothing for mild cases to topical treatments and biologics. The experts focus on biologics like Ixekizumab and Tofacitinib (Xeljanz), which have shown promise in treating both nail disease and psoriatic arthritis.Stay Connected For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode!